Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Anti-amyloid drugs

- PMLiVE

FDA briefing documents back Biogen’s Alzheimer’s drug aducanumab

Documents show the efficacy data for the drug as being ‘exceptionally persuasive’

- PMLiVE

Lilly’s Q3 earnings slump on COVID-19 development costs, pricing pressures

Earnings were particularly impacted by lower demand for top diabetes drug Trulicity

- PMLiVE

Eli Lilly ends COVID-19 antibody trial in hospitalised setting, other studies continue

Bamlanivimab is being studied in a number of additional ongoing trials

- PMLiVE

Roche and Atea link up for oral COVID-19 drug; UK to test coronavirus vaccine T cell responses

New developments for COVID-19 treatments and vaccines

- PMLiVE

Independent consultant will review Lilly’s COVID-19 plant issues

COVID-19 antibody trial was paused last week due to safety issue

- PMLiVE

Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b

Drug moves into late-stage testing despite failing to hit primary endpoint in previous trial

- PMLiVE

Lilly buys biotech firm Disarm Therapeutics for $135m

Deal could eventually be worth up to $1.36bn

- PMLiVE

Roche to collaborate with Dyno on gene therapies for CNS/liver diseases

Dyno will use its CapsidMap platform to develop novel AAV vectors for improved gene therapies

- PMLiVE

Eli Lilly’s COVID-19 antibody trial paused due to safety issue

Company has voluntarily paused study amid safety review

- PMLiVE

Lilly seeks US emergency approval after posting new data for COVID-19 antibodies

Combination of two antibodies reduced viral load and symptoms of COVID-19

- PMLiVE

FDA sets November date for expert panel review of Biogen’s aducanumab

Advisory committee will review biologics license application for controversial therapy

- PMLiVE

Lilly’s Verzenio scores a win in early-stage breast cancer

Positive data was presented at 2020 ESMO virtual congress

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links